Patents by Inventor Lifu Ma

Lifu Ma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 7-aminofuropyridine derivatives
    Patent number: 8378104
    Abstract: Compounds of Formula 1, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by TAK1 or for which an appropriate TAK1 inhibitor is effective. This Abstract is not limiting of the invention.
    Type: Grant
    Filed: February 11, 2011
    Date of Patent: February 19, 2013
    Assignee: OSI Pharmaceuticals, LLC
    Inventors: Keith R. Hornberger, Dan M. Berger, Xin Chen, Andrew P. Crew, Hanqing Dong, Andrew Kleinberg, An-Hu Li, Lifu Ma, Mark J. Mulvihill, Bijoy Panicker, Kam W. Siu, Arno G. Steinig, James G. Tarrant, Jing Wang, Qinghua Weng, Rajaram Sangem, Ramesh C. Gupta
  • 7-AMINOFUROPYRIDINE DERIVATIVES
    Publication number: 20120046267
    Abstract: Compounds of Formula 1, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by TAK1 or for which an appropriate TAK1 inhibitor is effective. This Abstract is not limiting of the invention.
    Type: Application
    Filed: February 11, 2011
    Publication date: February 23, 2012
    Inventors: Keith R. Hornberger, Dan M. Berger, Xin Chen, Andrew P. Crew, Hanqing Dong, Andrew Kleinberg, An-Hu Li, Lifu Ma, Mark J. Mulvihill, Bijoy Panicker, Kam W. Siu, Arno G. Steinig, James G. Tarrant, Jing Wang, Qinghua Weng, Rajaram Sangem, Ramesh C. Gupta
  • Substituted pyrrolo[2.3-B]pyridines
    Patent number: 7465726
    Abstract: Compounds represented by Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, are inhibitors of least two of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3?, EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, IGF-1R, Ron, Ret, and KDR kinases in animals, including humans, for the treatment and/or prevention of various diseases and conditions such as cancer.
    Type: Grant
    Filed: August 1, 2005
    Date of Patent: December 16, 2008
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Saleh Ahmed, Oscar Barba, Jason Bloxham, Graham Dawson, William Gattrell, John Kitchin, Neil Anthony Pegg, Imaad Saba, Shazia Sadiq, Colin Peter Sambrook Smith, Don Smyth, Amo G. Steinig, Robin Wilkes, Bijoy Panicker, Paula Tavares, Matthew Cox, An-Hu Li, Hanqing Dong, Lifu Ma, Kenneth (‘Ken’) Foreman, Qinghua (‘Felix’) Weng, Kathryn Stolz
  • HETEROCYCLIC BORONIC ACID COMPOUNDS
    Publication number: 20070185061
    Abstract: Dipeptidyl peptidase IV (DPP-IV)-inhibiting compounds are provided that have formula I: wherein n is 1 to 3; X is CH2; S; O; CF2 or C(CH3)2; Z is H; halogen; hydroxyl; (C1-6)alkoxy; (C1-12)alkyl; (C3-12)cycloalkyl; phenyl; or heteroaryl; where the phenyl and heteroaryl groups are optionally mono- or independently plurisubstituted with R7; optionally, X together with an adjacent ring carbon and Z form a fused cyclopropyl; and optionally, one of the bonds in the ring containing X is a double bond; and CRiRii, R1, R2, R3, R4 and R5 are as described herein.
    Type: Application
    Filed: November 6, 2006
    Publication date: August 9, 2007
    Inventors: David Campbell, David Winn, Juan Betancort, Kevin Shreder, Yi Hu, Bei Li, Melissa Wong, Lifu Ma, William Ripka, Min Wu
  • Site-specific, covalent bioconjugation of proteins
    Patent number: 7183392
    Abstract: Heterofunctional crosslinking groups are provided having the formula: wherein W is a covalent core component; L1, L2 and L3 are independently linking groups; X is a non-covalent or reversibly covalent protein tag binder; Y is a activatable covalent linking group; and Z is a protected or unprotected covalent crosslinking group.
    Type: Grant
    Filed: March 27, 2001
    Date of Patent: February 27, 2007
    Assignee: Zyomyx, Inc.
    Inventors: Peter Wagner, Lifu Ma, Steffen Nock, David Wilson, Jens Sydor
  • Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
    Publication number: 20060211678
    Abstract: Compounds represented by Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, are inhibitors of least two of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3?, EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, IGF-1R, Ron, Ret, and KDR kinases in animals, including humans, for the treatment and/or prevention of various diseases and conditions such as cancer.
    Type: Application
    Filed: August 1, 2005
    Publication date: September 21, 2006
    Inventors: Saleh Ahmed, Oscar Barba, Jason Bloxham, Graham Dawson, Wiliam Gattrell, John Kitchin, Neil Anthony Pegg, Imaad Saba, Shazia Sadiq, Colin Peter Sambrook Smith, Don Smyth, Amo Steing, Robin Wilkes, Bijoy Panicker, Paula Tavares, Matthew Cox, An-Hu Li, Hanqing Dong, Lifu Ma, Kenneth Foreman, Qinghua Weng, Kathryn Stolz
  • Site-specific, covalent bioconjugation of proteins
    Publication number: 20020013003
    Abstract: Heterofunctional crosslinking groups are provided having the formula: 1
    Type: Application
    Filed: March 27, 2001
    Publication date: January 31, 2002
    Inventors: Peter Wagner, Lifu Ma, Steffen Nock, David Wilson, Jens Sydor